Black Diamond Therapeutics financials
$1.87+2.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $70.0M | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $70.0M | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | 100.0% | — | — | — | — | — |
| Operating income | $12.5M | -$78.8M | -$86.5M | -$92.8M | -$126.9M | -$69.6M |
| Net income | $22.4M | -$69.7M | -$82.4M | -$91.2M | -$125.6M | -$67.3M |
| Net margin | 32.0% | — | — | — | — | — |
| Diluted EPS | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 | $-2.05 |
| EBITDA | $20.2M | -$78.4M | -$86.0M | -$92.3M | -$124.5M | -$67.8M |
| Operating cash flow | $29.6M | -$62.3M | -$66.7M | -$85.1M | -$100.1M | -$52.1M |
| Free cash flow | $29.6M | -$62.3M | -$66.8M | -$85.3M | -$102.9M | -$52.3M |
| Diluted shares | 57.6M | 55.0M | 44.0M | 36.3M | 36.2M | 32.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.0M | $36.4M | $56.2M | $34.3M | $65.8M | $34.6M |
| Short-term investments | $107.7M | $62.1M | $75.2M | $88.5M | $144.0M | $280.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $143.0M | $122.6M | $158.6M | $156.3M | $247.7M | $329.7M |
| Total liabilities | $30.8M | $39.4M | $41.8M | $40.6M | $51.8M | $21.9M |
| Shareholders' equity | $112.2M | $83.3M | $116.7M | $115.7M | $195.9M | $307.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology